13,14-Dihydro-15-keto-PGE2-d9

• CAT Number: S000843
• CAS Number: 2750534-81-5
• Molecular Formula: C20H23D9O5
• Molecular Weight: 361.52
• Purity: ≥95%
• IUPAC Name: (Z)-7-[(1R,2R,3R)-3-hydroxy-2-(5,5,6,6,7,7,8,8,8-nonadeuterio-3-oxooctyl)-5-oxocyclopentyl]hept-5-enoic acid
• InChI: InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-17,19,23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,19-/m1/s1/i1D3,2D2,3D2,6D2
• InChIKey: CUJMXIQZWPZMNQ-QNUVVDNFSA-N
• SMILES: [2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])CC(=O)CC[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O

13,14-Dihydro-15-keto-PGE2-d9（Cat No.:S000843）is a deuterated analog of 13,14-dihydro-15-keto-prostaglandin E2 (PGE2), a metabolite of the bioactive lipid prostaglandin E2. The “d9” indicates that nine hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen. This modification is used in research to trace the metabolic pathways and distribution of PGE2 in biological systems. PGE2 plays a critical role in inflammation, pain, and various physiological processes. The deuterated form is primarily employed in studies of prostaglandin metabolism, signaling, and the development of related therapeutic agents.

Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]